Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
Medtronic Cardiac Rhythm Disease Management · Decision date Oct 29, 2026
What did the FDA decide?
The FDA record for P010031/S934 covers a 30-Day Notice from Medtronic Cardiac Rhythm Disease Management concerning the Cobalt MRI CRT-D, Cobalt XT MRI CRT-D and Crome MRI CRT-D devices, classified under product code NIK as automatic implantable cardioverter defibrillators with cardiac resynchronization. The supplement reason is logged as a process change involving manufacturer, sterilizer, packager or supplier. Its stated purpose is to adjust the rise time measurement upper limit during final functional electrical testing.
S934 is a supplement to PMA P010031, so the identifier ties it to that original application rather than establishing a separate approval of the whole system. The notice describes a testing-limit adjustment, not a clinical study result, and no details are provided on the prior limit, the new limit, or the rationale. The entry therefore does not demonstrate safety or effectiveness on its own.
FDA approval order statement
to adjust rise time measurement upper limit during final functional electrical testing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010031/S934
- Regulatory pathway
- PMA supplement
- Product code
- NIK
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Product code
- NIK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010031 · Original PMA
CONCERTO/INSYNC SENTRY/INSYNC MAXIMO IMPLANTABLE CARDIOVASCULAR DEFIBRILLATORS WITH CARDIAC RESYNCHICNIZATION
P010031/S932 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S934 received
Application receipt date recorded by FDA.
P010031/S933 · Related supplement
Cobalt MRI CRT-D (DTPB2Dl, DTPB2D4, DTPB2Ql, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2Dl, DTPA2D4, DTPA2Ql, DTPA2QQ); Crome M
P010031/S934 · FDA decision
30-Day Notice
P010031/S931 · Related supplement
Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome M
Timeline entries are records held by MedtechLedger for P010031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA approval | Jun 26, 2002 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cardiac Rhythm Disease Management
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010031/S934
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


